MedX Seeks Final Extension to Complete $5 Million Convertible Note Financing

MedX Health ( (TSE:MDX) ) has provided an announcement.

MedX Health Corp. has applied to the TSX Venture Exchange for a final 30-day extension to May 15, 2026, to complete additional closings of its non-brokered private placement of Series IV Convertible Loan Notes, following an initial closing of $2.7 million. The company aims to raise up to a further $2.3 million through these notes, which carry a 6% annual interest rate, are convertible into units at $0.10 per unit, and include share purchase warrants exercisable at $0.125 until their December 31, 2028 maturity date.

The financing structure allows holders of already-matured Series I Convertible Loan Notes to roll into the new Series IV Notes and provides for agent commissions and warrants, while also anticipating participation by company insiders under existing minority protection rules. MedX plans to use the proceeds to redeem any remaining Series I Notes, advance development of its SIAscopy on DermSecure telemedicine platform, support the launch of its technology into the occupational health market, and for general corporate purposes, reinforcing its growth trajectory in digital dermatology and telehealth.

More about MedX Health

MedX Health Corp. is a Canada-based data-enabled medical technology company specializing in non-invasive skin screening and teledermatology through its proprietary SIAscopy imaging technology and DermSecure cloud platform. The company targets early detection of skin cancer and the expansion of digital dermatology and skin care services for clinical, investigational, and beauty and aesthetics markets across multiple regulated geographies, including Canada, the U.S., Europe, Australia, New Zealand, the U.K., and Turkey.

Average Trading Volume: 91,324

Technical Sentiment Signal: Sell

Current Market Cap: C$19.68M

For detailed information about MDX stock, go to TipRanks’ Stock Analysis page.